Phreesia, Inc. (NYSE:PHR) Given Average Recommendation of “Moderate Buy” by Brokerages

Phreesia, Inc. (NYSE:PHR) has been given a consensus recommendation of “Moderate Buy” by the fourteen ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $31.62.

A number of equities research analysts recently weighed in on PHR shares. Stephens restated an “overweight” rating and set a $28.00 price objective on shares of Phreesia in a research note on Friday, March 22nd. Raymond James reaffirmed an “outperform” rating and set a $30.00 target price (up from $25.00) on shares of Phreesia in a report on Friday, March 15th. Barclays began coverage on Phreesia in a report on Wednesday, January 3rd. They set an “overweight” rating and a $29.00 target price on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 target price on shares of Phreesia in a report on Thursday, March 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Phreesia in a report on Friday, March 15th.

Phreesia Stock Down 3.4 %

Shares of NYSE:PHR opened at $22.77 on Tuesday. Phreesia has a 52-week low of $12.05 and a 52-week high of $34.98. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -9.04 and a beta of 0.92. The company has a 50 day moving average of $24.64 and a two-hundred day moving average of $21.20.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The firm had revenue of $95.00 million for the quarter, compared to analysts’ expectations of $93.52 million. During the same period last year, the business posted ($0.72) earnings per share. The firm’s revenue for the quarter was up 24.0% on a year-over-year basis. As a group, analysts forecast that Phreesia will post -1.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Phreesia

In other news, COO Evan Roberts sold 25,962 shares of Phreesia stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $23.52, for a total transaction of $610,626.24. Following the completion of the sale, the chief operating officer now directly owns 728,570 shares in the company, valued at approximately $17,135,966.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Chaim Indig sold 12,043 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $22.62, for a total value of $272,412.66. Following the completion of the sale, the chief executive officer now directly owns 1,225,397 shares in the company, valued at approximately $27,718,480.14. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Evan Roberts sold 25,962 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $23.52, for a total value of $610,626.24. Following the completion of the sale, the chief operating officer now owns 728,570 shares of the company’s stock, valued at $17,135,966.40. The disclosure for this sale can be found here. Insiders have sold a total of 73,516 shares of company stock valued at $1,695,194 in the last 90 days. 5.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new stake in Phreesia in the 1st quarter worth approximately $43,000. Captrust Financial Advisors increased its position in Phreesia by 154.6% in the 2nd quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock worth $36,000 after buying an additional 866 shares during the period. International Assets Investment Management LLC increased its position in Phreesia by 1,987.3% in the 4th quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock worth $34,000 after buying an additional 1,411 shares during the period. State of Wyoming increased its position in Phreesia by 34.6% in the 2nd quarter. State of Wyoming now owns 1,918 shares of the company’s stock worth $59,000 after buying an additional 493 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Phreesia by 85.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,137 shares of the company’s stock worth $80,000 after buying an additional 1,445 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.